Price T Rowe Associates Inc Viracta Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $180,933 - $386,207	-81,136 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.37 - $7.91 $3.33 Million - $7.81 Million	-987,676 Reduced 92.41%	81,136 $296,000
Q3 2021 Nov 15, 2021	BUY	$7.84 - $12.53 $8.38 Million - $13.4 Million	1,068,812 New	1,068,812 $8.57 Million
Q2 2021 Aug 16, 2021	SELL	$7.55 - $12.95 $3.85 Million - $6.6 Million	-510,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$7.58 - $18.67 $3.87 Million - $9.52 Million	510,000 New	510,000 $4.72 Million

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $7.51M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.